Joseph M. Palumbo - Feb 16, 2023 Form 4 Insider Report for BIOVIE INC. (BIVI)

Role
Chief Medical Officer
Signature
/s/ Joseph M Palumbo, MD
Stock symbol
BIVI
Transactions as of
Feb 16, 2023
Transactions value $
-$30,310
Form type
4
Date filed
7/12/2024, 06:02 PM
Previous filing
Jan 18, 2023
Next filing
Jul 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIVI Common Stock Tax liability -$13.6K -2.48K -6.67% $5.51 34.7K Feb 16, 2023 Direct
transaction BIVI Common Stock Tax liability -$2.92K -2.48K -7.14% $1.18 32.2K Feb 15, 2024 Direct
transaction BIVI Common Stock Award $0 +116K +360.29% $0.00 148K Jun 24, 2024 Direct F1
transaction BIVI Common Stock Tax liability -$13.7K -29K -19.57% $0.47 119K Jun 24, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIVI Stock Option (right to buy) Award $0 +156K $0.00 156K Jun 24, 2024 Common Stock 156K $0.47 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on June 10, 2024, which grant became effective on June 24, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vested in full on June, 24, 2024.
F2 The options vest in three equal annual installments beginning on June 24, 2024.